Press coverage about Foundation Medicine (NASDAQ:FMI) has been trending positive on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a coverage optimism score of 0.26 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.1560944295475 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s analysis:

Several equities research analysts recently issued reports on the stock. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research raised shares of Foundation Medicine from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $45.33.

Foundation Medicine (FMI) opened at $59.40 on Friday. The company has a quick ratio of 2.03, a current ratio of 2.24 and a debt-to-equity ratio of 0.47. Foundation Medicine has a 12 month low of $17.10 and a 12 month high of $70.75.

Foundation Medicine (NASDAQ:FMI) last announced its earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.16. The company had revenue of $42.66 million during the quarter, compared to analyst estimates of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. Foundation Medicine’s revenue was up 45.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.90) earnings per share. sell-side analysts expect that Foundation Medicine will post -4.44 earnings per share for the current fiscal year.

In other news, COO Steven J. Kafka sold 3,201 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total value of $124,198.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jason Ryan sold 3,154 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $38.80, for a total transaction of $122,375.20. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 84,057 shares of company stock valued at $4,588,768. 2.70% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: “Favorable News Coverage Somewhat Unlikely to Affect Foundation Medicine (FMI) Share Price” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/favorable-news-coverage-somewhat-unlikely-to-affect-foundation-medicine-fmi-share-price/1764632.html.

About Foundation Medicine

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with Analyst Ratings Network's FREE daily email newsletter.